Last updated on December 2019

A Study of the Anti-PD1 Antibody PDR001 in Combination With Dabrafenib and Trametinib in Advanced Melanoma

Brief description of study

To evaluate the safety and efficacy of the combination of an anti-PD-1 antibody (Spartalizumab (PDR001)), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic BRAF V600 mutant melanoma

Clinical Study Identifier: NCT02967692

Find a site near you

Start Over

Novartis Investigative Site

Erlangen, Germany
  Connect »